Forthcoming receptor tyrosine kinase inhibitors

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 6, 2006, Pages 793-797

  Choong, Nicholas W ^a   Cohen, Ezra E W ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Chronic myelogenous leukaemia; Gastrointestinal stromal tumour; Tyrosine kinase inhibitor

Indexed keywords

4 METHYL N [3 (4 METHYL 1 IMIDAZOLYL) 5 (TRIFLUOROMETHYL)PHENYL] 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]BENZAMIDE; ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DOCETAXEL; ERLOTINIB; FLT3 LIGAND; GEFITINIB; IMATINIB; LAPATINIB; MONOCLONAL ANTIBODY; N (2 CHLORO 6 METHYLPHENYL) 2 [6 [4 (2 HYDROXYETHYL) 1 PIPERAZINYL] 2 METHYL 4 PYRIMIDINYLAMINO] 5 THIAZOLECARBOXAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER RESISTANCE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIDNEY CANCER; LUNG CANCER; PATIENT SELECTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; MUTATION; NEOPLASMS; PATIENT SELECTION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 33751397762     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.6.793     Document Type: Editorial

References (52)

1. BLUME-JENSEN P, HUNTER T Oncogenic kinase signalling. Nature (2001) 411:355-365.
2. HEHLMANN R, BERGER U, HOCHHAUS A: Chronic myeloid leukemia: a model for oncology. Ann. Hematol. (2005) 84:487-497.
3. ROY L, GUILHOT J, KRAHNKE T et al: Survival advantage from Imatinib compared to the combination Interferon-[alpha] plus cytarabine in chronic phase CML: historical comparison between two Phase III trials. Blood (2006) 108:1478-1484.
4. SLAMON DJ, LEYLAND-JONES B, SHAK S et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
5. VAN OOSTEROM AT, JUDSON I. VERWEIJ J et al.: Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358:1421-1423.
6. SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132.
7. DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med (2002) 347:472-480.
8. COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIPILI genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348:1201-1214.
9. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345.
10. HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial. growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:2544-2555.
11. VOKES EE, COHEN EE, MAUER AM et al.: A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck. Clin. Oncol. (2005) 23:Abstract 5504.
12. SALTZ LB, LENZ H, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J. Clin. Oncol. (2005) 23:Abstract 3508.
13. ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2:471-478.
14. MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327-337.
15. ADNANE L, TRAIL PA, TAYLOR I, WILHELM SM: Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. (2005) 407:597-612.
16. ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. (2005) 23:Abstract 4510.
17. EISEN T, OUDARD S, SZCZYLIK C et al.: Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: subgroup analysis of the approaches in renal cancer global evaluation trial (TARGETS). Ann. Oncol. (2006) 17:Abstract 446PD.
18. MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295:2516-2524.
19. MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (2006) 24:LBA3.
20. RINI BI, GEORGE DJ, MICHAELSON MD et al.: Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma. Ann. Oncol. (2006) 17:Abstract 4380.
21. TAMASKAR I, SHAHEEN P, WOOD L et al.: Antitumor effects of sorafenib and sunitinib in patients with metastatic renal cell carcinoma who had prior therapy with anti-angiogenic agents. J. Clin. Oncol. (2006) 24:Abstract 4597.
22. KIM TE, MURREN JR: Lapatinib ditosylate GlaxoSmithKline. IDrugs (2003) 6:886-893.
23. GEYER CE, FORSTER JK, CAMERON D et al.: A Phase III randomized, open-label, international study comparing lapatinib and capecitabine versus capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Proc. Am. Soc. Clin. Oncol. (2006) Scientific Special Session.
24. CAMERON D, GEYER CE, CHAN S et al.: Lapatinib in combination with capecitabine demonstrates superior efficacy compared with capecitabine alone in ERBB2+ advanced or metastatic breast cancer patients pretreated with chemotherapy and trastuzumab. Ann. Oncol. (2006) 17:Abstract 1410.
25. LIN NU, CAREY LA, LIU MC et al.: Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J. Clin. Oncol. (2006) 24:Abstract 503.
26. PEREZ EA, BYRNE JA, HAMMOND IW et al.: Cardian safety experience in 3127 patients treated with lapatinib. Ann. Oncol. (2006) 17:Abstract 1420.
27. NATALE RB, BODKIN D, GOVINDAN R et al.: ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized Phase II trial. J. Clin. Oncol. (2006) 24:Abstract 7000.
28. HEYMACH JV, JOHNSON BE, PRAGER D et al.: A Phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. J. Clin. Oncol. (2005) 24:Abstract 7016.
29. KOBAYASHI S, BOGGON TJ, DAYARAM T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2005) 352:786-792.
30. SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2:117-125.
31. CHEN LL, TRENT JC, WU EF et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. (2004) 64:5913-5919.
32. CORBIN AS, LA ROSEE P, STOFFREGEN EP, DRUKER BJ, DEININGER MW: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood (2003) 101:4611-4614.
33. KANTARJIAN H, GILES F, WUNDERLE L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354:2542-2551.
34. TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354:2531-2541.
35. KANTARJIAN H, GATTERMANN N, O'BRIEN S et al.: A Phase II study of AMN 107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia in chronic phase. J. Clin. Oncol. (2006) 24:Abstract 6534.
36. LE COUTRE PD, OTTMANN O, GATTERMAN N et al.: A Phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). J. Clin. Oncol. (2006) 24:Abstract 6531.
37. CORTES JE, KIM DW, ROSTI G et al.: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): results of the CA180006 'START-B' study. J. Clin. Oncol. (2006) 24:Absrract 6529.
38. SHAH NP, ROUSSELOT P, PASQUINI R et al.: Dasatinib (D) versus high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. J. Clin. Oncol. (2006) 24:Abstract 6507.
39. TALPAZ M, APPERLEY JF, KIM DW et al.: Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: results of the CA180005 'START-A' study. J. Clin. Oncol. (2006) 24:Abstract 6526.
40. HOCHHAUS A, KANTARJIAN H, BACCARANI M et al.: Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013' START-C' Study. J. Clin. Oncol. (2006) 24:Abstract 6508.
41. ESTROV Z, O'BRIEN S, GILES F et al.: Dasatinib (BMS354825), a dual Src-Abl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) following treatment failure with imatinib mesylate and AMN107. J. Clin. Oncol. (2006) 24:Abstract 6530.
42. REICHARDT P, CASALI PG, BLAY J et al.: A Phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J. Clin. Oncol. (2006) 24:Abstract 9545.
43. SCHITTENHELM MM, SHIRAGA S, SCHROEDER A et al: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. (2006) 66:473-481.
44. EVANS TR, MORGAN JA, VAN DEN ABBEELE AD et al.: Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J. Clin. Oncol. (2005) 23:Abstract 3034.
45. PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306-13311.
46. THATCHER N, CHANG A, PARIKH P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (2005) 366:1527-1537.
47. CLARK GM, CAMERON T, DAS GUPTA A: Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC. J. Clin. Oncol. (2006) 24:Abscract 7166.
48. EBERHARD DA, JOHNSON BE, AMLER LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. (2005) 23:5900-5909.
49. PAZ-ARES L, SANCHEZ JM, GARCÍA-VELASCO A et al.: A prospective Phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. (2006) 24:Abstract 7020.
50. MELLINGHOFF IK, WANG MY, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353:2012-2024.
51. HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21:4342-4349.
52. PAIK S, SHAK S, TANG G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. (2004) 351:2817-2826.